Mirimus is a company that creates innovative diagnostic and monitoring tools for better health decisions, translates early-stage research into customized RNAi and CRISPR Cas9 animal and cell models to accelerate drug development, and identifies and validates new drug targets to benefit people globally. Established in 2010, Mirimus harnesses the power of RNAi and genetic engineering technologies developed by its founders in leading labs.